Muscle Dysmorphia And Long-Term Anabolic Steroid Abuse: A 20-Year Case Report
Öz
Anahtar Kelimeler
Kaynakça
- Baggish A L, Weiner R B, Kanayama G, Hudson J I, Lu M T, Hoffmann U & Pope Jr H G. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21): 1991-2002. https://doi. org/10.1161/CIRCULATIONAHA.116.026945
- Bonnecaze A K, O’Connor T & Burns C A. (2021). Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021;36(7):2055-2064. https://doi.org/10.1007/s11606-021-06751-3
- Olivardia R, Pope Jr H G & Hudson J I. (2002). Muscle dysmorphia in male weightlifters: A case-control study. Am J Psychiatry. 2000;157(8):1291-1296. https://doi.org/10.1176/appi.ajp.157.8.1291
- Pope C G, Pope H G, Menard W, Fay C, Olivardia R & Phillips K A. (2005). Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body image. 2005;2(4): 395-400. https://doi.org/10.1016/j.bodyim.2005.09.001
- Van Amsterdam J, Opperhuizen A & Hartgens F. (2010). Adverse health effects of anabolic– androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117-123. https://doi.org/10.1016/j.yrtph.2010.02.001
Ayrıntılar
Birincil Dil
İngilizce
Konular
Madde Bağımlılığı Danışmanlığı, Davranışsal Epigenetik, Klinik Psikoloji
Bölüm
Olgu Sunumu
Yazarlar
Metin Çınaroğlu
*
0000-0001-6342-3949
Türkiye
Yayımlanma Tarihi
26 Temmuz 2024
Gönderilme Tarihi
9 Mart 2024
Kabul Tarihi
14 Mayıs 2024
Yayımlandığı Sayı
Yıl 2024 Cilt: 3 Sayı: 2